Compare PRCH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.9M | 806.3M |
| IPO Year | 2019 | 2019 |
| Metric | PRCH | CSTL |
|---|---|---|
| Price | $7.10 | $24.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $17.11 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 1.2M | 398.2K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | $344,229,000.00 |
| Revenue This Year | $3.86 | $2.42 |
| Revenue Next Year | $16.83 | $12.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | 3.66 |
| 52 Week Low | $4.65 | $14.59 |
| 52 Week High | $19.44 | $44.28 |
| Indicator | PRCH | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 26.58 |
| Support Level | $6.36 | $24.89 |
| Resistance Level | $9.89 | $34.97 |
| Average True Range (ATR) | 0.42 | 1.02 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 3.16 | 4.41 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.